Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0167 • ACR Convergence 2025
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Punith Chirumamilla¹, Sameer Kumar Majety², Rithish Nimmagadda³, Ravi Medarametla⁴, Priya Sunkara⁵, Pranathi Bandarupalli⁶, Anjani Mahesh Kumar Cherukuri⁷ and Himaja Anne⁸, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²School of Medicine, Xiamen University, China, Kakinada, Andhra Pradesh, India, ³One Brooklyn Health, New York, NY, ⁴Mamata Medical College, Guntur, Andhra Pradesh, India, ⁵White River Health, Batesville, AZ, ⁶Mercy St Vincent Medical Center, Toledo, OH, ⁷Guntur Medical College, Guntur, Andhra Pradesh, India, ⁸Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune, systemic disease with a rising U.S. healthcare burden. Utilizing Global Burden of Disease (GBD) 2021 estimates, we analyzed…
Abstract Number: 0087 • ACR Convergence 2025
Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Laura muñoz-Barrera¹, Carlos Pérez Sánchez², Rafaela Ortega-Castro³, Sagrario Corrales¹, Tomás Cerdó¹, Ismael Sanchez-Pareja¹, Pilar Font⁴, Jerusalen Calvo Gutierrez⁵, M Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez⁷, Pedro Seguí-Azpilcueta⁸, Christian Merlo-Ruiz⁶, Jose Javier Pérez Venegas⁹, DOLORES RUIZ MONTESINOS¹⁰, Carmen Maria Romero Barco¹¹, Antonio Fernández-Nebro¹², Natalia Mena Vázquez¹³, FRANCISCO JAVIER GODOY NAVARRETE¹⁴, ALBA MARIA CABEZAS LUCENA¹⁵, MARIA ANGELES AGUIRRE ZAMORANO¹, Nuria Barbarroja¹⁶, Alejandro Escudero¹⁷ and Chary López pedrera¹⁸, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, ⁸Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ¹⁰Virgen Macarena University Hospital, Sevilla, Spain, Cordoba, ¹¹Virgen de la Victoria Hospital Malaga, Spain, Malaga, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ¹⁴Jaen University Hospital, Spain, Jaen, Spain, ¹⁵Jaen University Hospital, Spain, Jaen, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Lipid metabolism plays a key role in immune cell plasticity, influencing activation, differentiation and function. Inflammation alters this metabolism, contributing to disease progression. Extensive…
Abstract Number: 0069 • ACR Convergence 2025
Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions
Camilla R.L. Machado¹, Mina Yao¹, David Boyle², Robert J. Benschop³, James T. Parker³, Wei Wang² and Gary Firestein¹, ¹University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, ³Eli Lilly, San Diego
Background/Purpose: RA synovium displays cellular heterogeneity, with gene expression driving disease pathogenesis. Unbiased cell-specific transcriptomes in RA synovium have previously relied primarily on disaggregated tissues…
Abstract Number: 0033 • ACR Convergence 2025
Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
Lauren Vanderlinden¹, Jun Inamo², Jennifer Seifert³, V. Michael Holers⁴, Joel Guthridge⁵, Kevin Deane⁶ and Fan Zhang⁷, ¹University of Colorado Anschutz Medical Campus, Monument, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁷The University of Colorado, Aurora, CO
Background/Purpose: Human leukocyte antigen (HLA) class II genes play a central role in antigen presentation and immune modulation. The shared epitope (SE) region within HLA-DRB1…
Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Ricardo Grieshaber-Bouyer¹, Jamie Haddon², Maria Gabriella Raimondo³, Carlo Tur³, Sebastian Böltz³, Tobias Dashi⁴, Melanie Hagen⁵, Andreas Wirsching³, Tobias Rathe⁴, Xuan Wu⁶, Peter Wung², Francis Kim², Yonghong Zhu⁶, Ken Song², Timothy Lu⁷ and Georg Schett⁸, ¹University Hospital Erlangen, Erlangen, Germany, ²Candid Therapeutics, San Diego, CA, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine ³- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ⁶EpimAb Biotherapeutics, Shanghai, China (People's Republic), ⁷Candid Therapeutics, San Diego, ⁸Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Peter Taylor¹, Jason Carlson², Shirley Vu², Signe Fransen³, Diana Abdueva⁴ and Jeffrey Curtis⁵, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual, sf, CA, ⁴Aqtual, Hayward, CA, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
Abstract Number: 2258 • ACR Convergence 2025
Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease
Sanjita Gowda¹, Yuri Matusov², Amara Seng¹, Nunzio Bottini³ and Jon Giles⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, ³Cedars Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Pulmonary diseases are contributors to the morbidity and mortality of RA. Despite the recent surge in studies of RA-associated interstitial lung disease (RA-ILD), there…
Abstract Number: 2241 • ACR Convergence 2025
RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
Hugo PENSEC¹, Alain SARAUX², florent garrigues³, yoann le duault¹, sandrine jousse⁴, baptiste quere⁴, nathan foulquier⁵, Valerie Devauchelle⁶ and ikram brahim⁷, ¹CHRU Brest, Brest, France, ²CHU Brest, Brest, France, ³CHU de BREST, Brest, Bretagne, France, ⁴LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ⁵LBAI, UMR¹²²⁷, Univ Brest, Inserm, Brest, France, Brest, France, ⁶UBO, Brest, France, ⁷CHRU, LBAI, UMR¹²²⁷, Univ Brest, Inserm, LaTIM, UMR ¹¹⁰¹, Brest, France, Brest, France
Background/Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory disorder inducing joint space narrowing and erosion at both hands and feet. Reading of X-ray images remains…
Abstract Number: 2208 • ACR Convergence 2025
Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
Catherine Sims¹, Yujung Choi², Abigail Shapiro³, Elizabeth Strawbridge², Jennifer Gierisch¹, Teresa Howard², Ankoor Shah¹ and Karen Goldstein¹, ¹VA Durham Healthcare System, Duke University, Durham, ²VA Durham Healthcare System, Durham, ³VA Durham Healthcare System, Cleveland
Background/Purpose: More than 8,500 women Veterans carry a diagnosis of rheumatoid arthritis (RA), however, there are limited data on the reproductive health and experiences of…
Abstract Number: 1950 • ACR Convergence 2025
Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Frederik Enevoldsen¹, Sarah Ormseth², Dzenan Masic¹, Matthew Budoff³, Ellen-Margrethe Hauge¹ and George Karpouzas³, ¹Aarhus University, Aarhus, Denmark, ²The Lundquist Institute for Biomedical Innovation, Torrance, CA, ³Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Pericoronary adipose tissue attenuation (PCATa) reflects the composition of the fat directly surrounding the coronary arteries and is associated with coronary wall inflammation. In…
Abstract Number: 1885 • ACR Convergence 2025
Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study
Carl Turesson¹, Linnea arvidsson², Emil Rydell¹ and Ulf Bergström³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Smoking is an established risk factor for rheumatoid arthritis (RA), and there is also evidence for an association with socioeconomic factors. As RA is…
Abstract Number: 1702 • ACR Convergence 2025
Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease
Yakir Reshef¹, Lakshay Sood¹, Michelle Curtis¹, Laurie Rumker², DANIEL STEIN³, Mukta Palshikar¹, Saba Nayar⁴, Andrew Filer⁵, Anna Helena Jonsson⁶, ilya Korsunsky⁷ and Soumya Raychaudhuri⁷, ¹Brigham and Women's Hospital, Boston, ²Broad Institute, Boston, ³Harvard University, Boston, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵The University of Birmingham, Birmingham, United Kingdom, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
Abstract Number: 1645 • ACR Convergence 2025
A sex-modified association between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) blood concentration and prevalent arthritis among young and middle-aged US adults
Queeneth Edwards¹, Samuel Mbadu¹, Jhy-Charm Soo² and Jian Zhang², ¹Georgia Southern University, Statesboro, GA, ²Georgia Southern University, statesboro
Background/Purpose: Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) (PFAS), including Perfluorooctanoic acid (PFOA) and Perfluorooctane sulfonate (PFOS), are persistent environmental contaminants that may influence inflammatory joint diseases…
Abstract Number: 1363 • ACR Convergence 2025
Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Naoki Kondo and Nariaki Hao, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: The aim is to examine the efficacy and safety of baricitinib (BARI) in Japanese rheumatoid arthritis (RA) patients in real clinical practice and is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].